Lupin Ltd on Thursday said it has received American health regulator’s approval to market Escitalopram tablets, used in treating depressive disorders, in the US market.
The company’s subsidiary Lupin Pharmaceuticals Inc has received final approval from US Food and Drug Administration (USFDA) for its Escitalopram tablets in strengths of 5 mg, 10 mg, and 20 mg, Lupin said in a statement.
Lupin’s product is the generic version of Forest Laboratories Inc’s Lexapro tablets and is indicated for treatment of major depressive disorder in adults and adolescents aged 12—17 years as also for the acute treatment of general anxiety disorder in adults.
Lexapro tablets had annual US sales of around $2.7 billion for the year ending March, 2012.
Shares of Lupin closed at Rs 599.20 on the BSE, down 3.19 per cent from their previous close.